Neuron23

📍 South San Francisco, United States🗓 Founded 2018👥 57 employees💰 Last funded Oct 2024
Biotechnology Research🌐 neuron23.com
Website LinkedIn
Neuron23™ Inc. is a leading clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The Company’s focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Founded in 2018, Neuron23 has assembled a world-class team of experts and entrepreneurs located in South San Francisco, CA.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2018
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United Kingdom
1
Frequently asked questions
Who invested in Neuron23?
Neuron23 has 1 investors on record on gritt.io and 1 late-stage investors.
When did Neuron23 last raise funding?
The most recent investment in Neuron23 recorded on gritt.io was in October 2024.
When was Neuron23 founded?
Neuron23 was founded in 2018.
What industry is Neuron23 in?
Neuron23 operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Neuron23 based?
Neuron23 is headquartered in South San Francisco, United States.